Leerink Partners analyst Daina Graybosch has maintained their bullish stance on MRK stock, giving a Buy rating on April 25.
Daina Graybosch’s rating is based on Merck & Company’s strategic efforts to mitigate macroeconomic risks and uncertainties. The company has shown resilience by transitioning to a local manufacturing model and building inventory to counter potential pharma-sector tariffs. Additionally, Merck’s management has provided reassuring commentary on their regulatory discussions, suggesting minimal disruption from FDA changes.
Furthermore, Merck’s pipeline, particularly in the cardiometabolic and pulmonary sectors, offers potential upside with promising trials such as the Phase 3 enlicitide trials and the high-risk, high-reward CADENCE trial. Despite concerns over the Keytruda 2028 loss-of-exclusivity and IRA overhang, there is a belief that sentiment towards Merck’s shares could improve, especially given the company’s recent performance and strategic initiatives.
In another report released on April 25, Citi also maintained a Buy rating on the stock with a $115.00 price target.
MRK’s price has also changed moderately for the past six months – from $103.980 to $82.740, which is a -20.43% drop .